Barril Guillermina, Castillo Inmaculada, Arenas María Dolores, Espinosa Mario, Garcia-Valdecasas Juan, Garcia-Fernández Nuria, González-Parra Emilio, Alcazar José María, Sánchez Carmen, Diez-Baylón José Carlos, Martinez Pilar, Bartolomé Javier, Carreño Vicente
Department of Nephrology, Hospital de Princesa, Madrid, Spain.
J Am Soc Nephrol. 2008 Dec;19(12):2288-92. doi: 10.1681/ASN.2008030293. Epub 2008 Aug 6.
Occult hepatitis C virus (HCV) infection (i.e., detectable HCV-RNA in the liver or peripheral blood mononuclear cells) in the absence of both serum HCV-RNA and anti-HCV antibodies has not been investigated in hemodialysis patients. In this study, real-time PCR and in situ hybridization was used to test for the presence of genomic and antigenomic HCV-RNA in peripheral blood mononuclear cells of 109 hemodialysis patients with abnormal levels of liver enzymes. Occult HCV infection, determined by the presence of genomic HCV-RNA, was found in 45% of the patients; 53% of these patients had ongoing HCV replication, indicated by the presence of antigenomic HCV-RNA. Patients with occult HCV infection had spent a significantly longer time on hemodialysis and had significantly higher mean alanine aminotransferase levels during the 6 mo before study entry. Logistic regression analysis revealed that mortality was associated with age >60 yr (odds ratio 3.30; 95% confidence interval 1.05 to 10.33) and the presence of occult HCV infection (odds ratio 3.84; 95% confidence interval 1.29 to 11.43). In conclusion, the prevalence of occult HCV infection is high among hemodialysis patients with persistently abnormal values of liver enzymes of unknown cause. The clinical significance of occult HCV infection in these patients requires further study.
在血液透析患者中,尚未对血清丙型肝炎病毒(HCV)RNA和抗-HCV抗体均不存在的情况下的隐匿性HCV感染(即肝脏或外周血单个核细胞中可检测到HCV-RNA)进行研究。在本研究中,采用实时PCR和原位杂交技术检测了109例肝酶水平异常的血液透析患者外周血单个核细胞中基因组和反基因组HCV-RNA的存在情况。通过基因组HCV-RNA的存在确定的隐匿性HCV感染在45%的患者中被发现;其中53%的患者存在HCV持续复制,这通过反基因组HCV-RNA的存在得以表明。隐匿性HCV感染患者在血液透析上花费的时间显著更长,并且在研究入组前6个月期间平均丙氨酸转氨酶水平显著更高。逻辑回归分析显示,死亡率与年龄>60岁(比值比3.30;95%置信区间1.05至10.33)以及隐匿性HCV感染的存在(比值比3.84;95%置信区间1.29至11.43)相关。总之,在病因不明的肝酶持续异常的血液透析患者中,隐匿性HCV感染的患病率很高。隐匿性HCV感染在这些患者中的临床意义需要进一步研究。